Our study revealed that treatment with hsBCL9z96 significantly enhanced the proportions of IFN-γ+ CD8+, Granzyme B+ CD8+ and Ki67+ CD8+ T cells in tumor-infiltrating lymphocytes (TILs), as well as in tumor-draining lymph nodes (TdLN) and spleens from hsBCL9z96-treated CT26 tumor-bearing mice (Supplementary Fig. 4c–f). This evidence concerns the gene CD8A and neoplasm.